Compare Amylx Pharmaceuticals Inc (AMLX) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Hershey Co — how do they compare? Amylx Pharmaceuticals Inc trades at $23.55 (market cap $2.64B), while Hershey Co trades at $183.84 (market cap $36.56B). The key difference: Hershey Co is far larger — about 13.8× Amylx Pharmaceuticals Inc's market cap, and Hershey Co pays a 3.19% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | HSY | |
|---|---|---|
Market Cap | $2.64B | $36.56B |
Sector | Health | Consumer Staples |
52-Week High | $24.19 | $236.28 |
52-Week Low | $7.82 | $162.31 |
Enterprise Value | $2.39B | $41.70B |
Dividend Yield | — | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.61, up 4.15% today, with strong analyst support (91% buy ratings) and a $30 consensus price target. The stock shows bullish technical momentum despite negative profitability metrics (ROE -74.73%, ROA -66.25%). Recent Q2 2026 earnings missed expectations, but the company maintains $250.8M cash runway into 2028, supporting its pivotal Phase 3 LUCIDITY trial readout expected August-September 2026.
The investment thesis hinges on successful avexitide clinical outcomes, with potential 2027 launch offering significant upside. Key risks include ongoing financial losses, clinical trial execution, and competitive pressures. Current valuation at 11.02x book value appears stretched given negative earnings, making positive trial results critical for justifying premium pricing.
Hershey (HSY) trades at $183.19, up 0.24% with strong technical momentum and bullish moving average signals. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates by 33% and revenue growth of 4.5-5% guidance. Recent earnings show significant margin recovery to 45.3% as cocoa prices decline, supporting the stock's premium valuation at 24.86 P/E. Analyst consensus price target of $196.78 suggests 7.4% upside potential from current levels.
HSY presents a compelling investment case with improving fundamentals, dividend growth resumption, and margin expansion. However, risks include volume declines in salty snacks, competitive pressures, and potential cocoa price volatility. The stock's current technical overbought condition near resistance at $184 warrants caution despite positive earnings momentum and institutional support.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
